Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 t...
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
About this item
Full title
Author / Creator
Li, Jingxin , Hou, Lihua , Guo, Xiling , Jin, Pengfei , Wu, Shipo , Zhu, Jiahong , Pan, Hongxing , Wang, Xue , Song, Zhizhou , Wan, Jingxuan , Cui, Lunbiao , Li, Junqiang , Chen, Yin , Wang, Xuewen , Jin, Lairun , Liu, Jingxian , Shi, Fengjuan , Xu, Xiaoyu , Zhu, Tao , Chen, Wei and Zhu, Fengcai
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant ade...
Alternative Titles
Full title
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8863573
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8863573
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-021-01677-z
